Minerva Neurosciences, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Minerva is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its lead candidate, roluperidone, is under FDA review for negative symptoms of schizophrenia; MIN-301 is being developed for Parkinson’s disease.
Key financial metrics
| Metric | Q2 2023 / June 30, 2023 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.9 million for Q2; $4.5 million for first half | $4.1 million and $9.1 million, respectively, in 2022 |
| General and administrative expense | $2.6 million for Q2; $5.3 million for first half | $2.8 million and $5.9 million, respectively, in 2022 |
| Net loss | $6.2 million for Q2; $13.2 million for first half | $8.7 million and $18.5 million, respectively, in 2022 |
| Basic and diluted loss per share | $1.12 for Q2; $2.43 for first half | $1.63 and $3.46, respectively, in 2022 |
| Cash, cash equivalents and restricted cash | $51.9 million | $36.2 million at December 31, 2022 |
| Operating cash use | $4.0 million for first half | $11.0 million in first half 2022 |
| Total assets / total liabilities | $67.1 million / $79.6 million | $55.1 million / $75.1 million at December 31, 2022 |
| Stockholders’ equity (deficit) | $(12.5) million | $(20.0) million at December 31, 2022 |
There is no meaningful product gross margin because the company has no product revenue. The $77.7 million liability related to the sale of future seltorexant royalties is the principal long-term liability; it is accounted for as debt, with non-cash interest expense. The filing reports no outstanding term loans, which were repaid in 2018.
Changes versus prior periods
- Q2 net loss narrowed by about 29% year over year; first-half net loss narrowed by about 29%. Expense reductions, particularly lower R&D spending, were partly offset by higher non-cash royalty interest expense.
- R&D expense fell 54% in Q2 and 51% for the first half, mainly reflecting lower stock-based compensation and consultant costs after the roluperidone NDA preparation in 2022. G&A expense declined 7% in Q2 and 10% for the first half.
- First-half operating cash use declined to $4.0 million from $11.0 million. The comparison benefited from the $3.1 million FDA user-fee refund received in January 2023, as well as non-cash adjustments and working-capital movements.
- June financing provided $20.0 million gross, or $19.7 million net, through a private placement. It included 1,425,000 common shares and pre-funded warrants for 575,575 shares. Common shares outstanding rose to 6,993,406 from 5,340,193 at year-end 2022.
Outlook, developments and risks
- The FDA filed the roluperidone NDA on April 27, 2023, after granting Minerva’s appeal of its prior refusal-to-file decision. The FDA assigned standard review and a February 26, 2024 PDUFA goal date, but flagged potential review issues previously raised, including antipsychotic interaction and safety questions, applicability of non-U.S. data to U.S. patients, efficacy evidence, and identifying patients likely to benefit.
- The efficacy evidence is mixed: the Phase 2b study met its primary hypothesis, while the Phase 3 study’s primary intent-to-treat analysis did not reach statistical significance (p=0.064); a modified intent-to-treat analysis showed a nominally significant result (p=0.044). The company seeks approval for the 64 mg dose.
- Management believes available cash will fund operating commitments for at least 12 months from the financial-statement issuance date. It expects continued losses and negative operating cash flow and says additional capital will be needed to continue operations and fully fund potential later-stage development. Financing may not be available on acceptable terms; without it, programs or operations could be scaled back or discontinued.
- The royalty liability increased to $77.7 million, including $4.0 million of first-half non-cash interest expense. Its estimated effective annual interest rate was approximately 10.7%; the calculation depends on uncertain future royalty and milestone-payment assumptions.
- Minerva regained compliance with Nasdaq’s minimum market-value listing requirement in June 2023. Management reported effective disclosure controls and no material changes in internal control over financial reporting. The company reported no legal proceeding expected to have a material adverse effect.
- No formal financial guidance was provided. Key risks include FDA review or approval delays or denial, further clinical or regulatory requirements, ongoing funding needs and dilution, and the absence of commercial revenue. The filing also describes cybersecurity, privacy, international regulatory and reimbursement risks.
Important facts for investors to verify
- Track FDA review milestones and whether the identified roluperidone issues can be resolved without additional studies or a complete response letter.
- Review the full Phase 2b and Phase 3 efficacy and safety data, especially the Phase 3 intent-to-treat result versus the modified analysis.
- Assess cash burn and runway against the stated 12-month commitment estimate, including anticipated costs for regulatory work and any commercial preparations.
- Confirm the effects of the private placement and pre-funded warrants on share count and potential dilution; check the required resale registration filing.
- Monitor the Royalty Pharma liability and the assumptions driving its interest accretion, as well as the status of Janssen’s two ongoing Phase 3 seltorexant studies and potential milestones.